Georgiana Toma: Addressing Iron Deficiency Without Anemia
Georgiana Toma, Hematology resident at the University Emergency Hospital of Bucharest, shared a post on LinkedIn:
“Iron Deficiency Without Anemia
How many of our patients struggle with chronic fatigue, ‘brain fog’, or exercise intolerance, only to be told their labs are ‘perfectly normal’ because their Hemoglobin is within range?
As clinicians, we are trained to treat Anemia.
But modern Hematology is sounding the alarm on a much more subtle predator: Iron Deficiency Without Anemia (IDWA).
The ‘Normal Hemoglobin’ Trap
A patient can have a Hemoglobin of 14 g/dL and still be cellularly ‘starving’ for iron.
Iron isn’t just for making red blood cells; it’s a critical cofactor for mitochondrial function, DNA synthesis, and neurotransmitter metabolism.
When we only look at the CBC, we miss the Sideropenia that is sabotaging our patients’ recovery and quality of life.
A Multidisciplinary challenge:
The evidence for treating IDWA (typically defined as Ferritin <30–50 ng/mL) is now robust across specialties:
- cardiology: the FAIR-HF and CONFIRM-HF trials revolutionized the field. Correcting iron deficiency in heart failure patients—regardless of anemia status—improves ejection fraction and reduces hospitalizations.
- neurology: iron is the ‘engine’ for dopamine synthesis. In Restless Legs Syndrome (RLS), clinical guidelines now suggest targeting Ferritin levels above 75 ng/mL, far beyond standard ‘normal’ lab ranges.
- gynecology: we often focus on stopping the flow (menorrhagia) but neglect the cognitive and physical toll of depleted iron stores that persist long after the bleeding is managed.
- sportsmedicine : sideropenia impairs muscular oxidative capacity and increases lactate production, even when oxygen-carrying capacity (Hb) is intact.
Should we stop asking ‘Is the patient anemic?’ and start asking ‘Are the patient’s iron stores optimized for their specific pathology?’
Standard lab ranges for Ferritin (often starting at 15 ng/mL) frequently fail to account for the functional needs of a failing heart or a developing brain.”
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 19, 2026, 15:01Erik Nelson: The Biomarker that Connects Heart, Brain, and DNA
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs